Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

  • WCLC 2016

    17th World Conference on Lung Cancer

    Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria

    Presentation Date(s):  
    • Dec 4 - 7, 2016
    • Total Presentations: 2466

    To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.

    Presentations will be available 24 hours after their live presentation time

    IASLC Member Price: $0.00 USD
    Enter Virtual Meeting Access Code
Filter Results:

Show Only Available Presentations

  • +

    OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC

    • Type: Oral Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 8
    • Moderators:L. Crinò
    • Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
    • +

      OA03.01 - First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 (Abstract under Embargo until December 5, 7:00 CET)

      11:00 - 11:10  |  Author(s): S.N. Gettinger

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      OA03.02 - Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study

      11:10 - 11:20  |  Author(s): M.C. Garassino

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    SC14 - Immunotherapy of NSCLC

    • Type: Science Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 5
    • Moderators:N. Rizvi
    • Coordinates: 12/06/2016, 11:00 - 12:30, Hall C2
  • +

    SC22 - Selection and Monitoring of Patients for Immune Checkpoint Inhibitors

    • Type: Science Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 5
    • Moderators:G.V. Scagliotti
    • Coordinates: 12/06/2016, 16:00 - 17:30, Hall C8
  • +

    PL04a - Plenary Session: Immune Checkpoint Inhibitors in Advanced NSCLC

    • Type: Plenary
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 5
    • Moderators:J. Soria
    • Coordinates: 12/07/2016, 08:45 - 09:40, Hall D (Plenary Hall)
    • +

      PL04a.03 - Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study (Abstract under Embargo until December 7, 7:00 CET)

      09:05 - 09:15  |  Author(s): M.C. Garassino

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    OA20 - Immunotherapy and Markers

    • Type: Oral Session
    • Track: Biology/Pathology
    • Presentations: 8
    • Moderators:M. Früh
    • Coordinates: 12/07/2016, 11:00 - 12:30, Stolz 2
    • +

      OA20.01 - Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

      11:00 - 11:10  |  Author(s): M. Kowanetz

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    ISS12 - Immuno–Oncology: A Renaissance in the Treatment of Lung Cancer – MSD Oncology

    • Type: Industry Supported Symposium
    • Track:
    • Presentations: 7
    • Moderators:D.P. Carbone
    • Coordinates: 12/07/2016, 12:45 - 14:15, Lehar 3-4
    • +

      ISS12.02 - Immunotherapy Experience in Lung Cancer

      12:50 - 13:05  |  Author(s): N. Rizvi

      • Abstract

      No abstract available for this presentation